Learning Objectives:

  1. To understand how Vericiguat was studied in patients with HFrEF
  2.  To critically assess the utility of Vericiguat in HFrEF and what patient population would benefit from the same.



Session date: 
11/12/2021 - 7:30am to 8:30am CST
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Kifah Hussain, MD